CN104394872A - 用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法 - Google Patents
用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法 Download PDFInfo
- Publication number
- CN104394872A CN104394872A CN201380031029.XA CN201380031029A CN104394872A CN 104394872 A CN104394872 A CN 104394872A CN 201380031029 A CN201380031029 A CN 201380031029A CN 104394872 A CN104394872 A CN 104394872A
- Authority
- CN
- China
- Prior art keywords
- administration
- compositions
- orotate
- adenine
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/446,328 US8653090B2 (en) | 2008-03-12 | 2012-04-13 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
US13/446,328 | 2012-04-13 | ||
PCT/US2013/036326 WO2013155385A1 (en) | 2012-04-13 | 2013-04-12 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104394872A true CN104394872A (zh) | 2015-03-04 |
Family
ID=49328189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380031029.XA Pending CN104394872A (zh) | 2012-04-13 | 2013-04-12 | 用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2836217A4 (ja) |
JP (1) | JP2015518000A (ja) |
CN (1) | CN104394872A (ja) |
IN (1) | IN2014DN09546A (ja) |
WO (1) | WO2013155385A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10736557B2 (en) | 2016-03-30 | 2020-08-11 | Brain F.I.T. Imaging, LLC | Methods and magnetic imaging devices to inventory human brain cortical function |
US11337631B2 (en) | 2017-10-03 | 2022-05-24 | Brainn F.I.T. Imaging, LLC | Methods and magnetic imaging devices to inventory human brain cortical function |
CA3135689A1 (en) | 2019-04-03 | 2020-10-08 | Brain F.I.T. Imaging, LLC | Methods and magnetic imaging devices to inventory human brain cortical function |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130035A (en) * | 1998-02-20 | 2000-10-10 | Brusilow Enterprise Llc | Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening |
WO2005077365A2 (en) * | 2004-02-12 | 2005-08-25 | Istituto Superiore di Sanità | Novel uses for proton pump inhibitors |
US20110077260A1 (en) * | 2002-02-12 | 2011-03-31 | Ford John P | Methods, compositions, and kits for organ protection during systemic anticancer therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979688B2 (en) * | 2002-02-12 | 2005-12-27 | Ford John P | Treatment method against side-effects of chemotherapy |
US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
US7470672B2 (en) * | 2006-07-31 | 2008-12-30 | Savvipharm Inc. | Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives |
-
2013
- 2013-04-12 WO PCT/US2013/036326 patent/WO2013155385A1/en active Application Filing
- 2013-04-12 CN CN201380031029.XA patent/CN104394872A/zh active Pending
- 2013-04-12 EP EP13775759.7A patent/EP2836217A4/en not_active Withdrawn
- 2013-04-12 JP JP2015505934A patent/JP2015518000A/ja active Pending
-
2014
- 2014-11-13 IN IN9546DEN2014 patent/IN2014DN09546A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130035A (en) * | 1998-02-20 | 2000-10-10 | Brusilow Enterprise Llc | Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening |
US20110077260A1 (en) * | 2002-02-12 | 2011-03-31 | Ford John P | Methods, compositions, and kits for organ protection during systemic anticancer therapy |
WO2005077365A2 (en) * | 2004-02-12 | 2005-08-25 | Istituto Superiore di Sanità | Novel uses for proton pump inhibitors |
Non-Patent Citations (2)
Title |
---|
LIAN, T. 等: "Trends and developments in liposome drug delivery systems", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
VERMA等: "Osmotically controlled oral drug delivery", 《DEVELOPMENT AND INDUSTRIAL PHARMACY》 * |
Also Published As
Publication number | Publication date |
---|---|
JP2015518000A (ja) | 2015-06-25 |
IN2014DN09546A (ja) | 2015-07-17 |
EP2836217A4 (en) | 2015-10-28 |
WO2013155385A1 (en) | 2013-10-17 |
EP2836217A1 (en) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11077078B2 (en) | Compositions and methods for the treatment of cancer | |
EP2262478B1 (en) | Activated nitric oxide donors and methods of making and using thereof | |
EP2391363B1 (en) | Compositions and methods for the treatment of cancer | |
CN103221040A (zh) | 双硫仑制剂及用途 | |
JP2010511039A5 (ja) | ||
US8653090B2 (en) | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents | |
CN104394872A (zh) | 用于治疗与癌症化学治疗剂的给药相关的副作用的组合物和方法 | |
US20140287000A1 (en) | Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation by using tumor proliferation inhibitor and low-intensity pulsed ultrasound waves | |
CN101721417A (zh) | 一种治疗胃肠道恶性肿瘤的胃内滞留漂浮缓释片 | |
US9119855B2 (en) | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents | |
CN102060722B (zh) | 一种含砷化合物及其制备方法和用途 | |
US20090232884A1 (en) | Composition and method for treatment of the side-effects associated with administration of cancer chemotherapeutic agents | |
EP3563856B1 (en) | Pharmaceutical composition comprising capecitabine, gimeracil, and oteracil for treating cancer and use thereof | |
EP2665489B1 (en) | A combination comprising an adenoviral vector having a thymidine kinase gene, ganciclovir and temozolomide for use in the treatment of glioblastoma multiform | |
ZA200603019B (en) | Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof | |
CN116139161A (zh) | Hdac抑制剂联合抗代谢物在抗乳腺癌中的用途 | |
Kavitha | Targeted Drug Delivery of Anti Cancer Drug by Applying Gastro Retentive Systems and Its Pharmacological Evaluation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150304 |
|
WD01 | Invention patent application deemed withdrawn after publication |